2019EHF指南_应用单克隆抗体作用降钙素基因相关肽或其受体预防偏头痛.pdfVIP

Sacco et al. The Journal of Headache and Pain (2019) 20:6 The Journal of Headache /10.1186/s10194-018-0955-y and Pain CONSENSUS ARTICLE Open Access European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention 1* 2 2 3 4 Simona Sacco , Lars Bendtsen , Messoud Ashina , Uwe Reuter , Gisela Terwindt , Dimos-Dimitrios Mitsikostas5† and Paolo Martelletti6† Abstract Background and aim: Monoclonal antibodies acting on the calcitonin gene-related peptide or on its receptor are new drugs to prevent migraine. Four monoclonal antibodies have been developed: one targeting the calcitonin gene-related peptide receptor (erenumab) and three targeting the calcitonin gene-related peptide (eptinezumab, fremanezumab, and galcanezumab). The aim of this document by the European Headache Federation (EHF) is to provide an evidence-based and expert-based guideline on the use of the monoclonal antibodies acting on the calcitonin gene-related peptide for migraine prevention. Methods: The guideline was developed following the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) approach. The working group identified relevant questions, performed systematic review and analysis of the literature, assessed the quality of available evidence, and wrote recommendations. Where the GRADE approach was not applicable, expert opinion was provided. Results: We found low to high quality of evidence to recommend eptinezumab, erenumab, fremanezumab, and galcanezumab i